GET DAILY SIGNALSClearPoint Neuro (CLPT) Posts 36% Revenue Growth in Q3 Despite Mixed Results
Key Takeaways
- Total revenue reached $12.08 million in the third quarter of 2026, up 36% from $8.86 million a year earlier.
- Product revenue climbed 47% to $7.89 million, while service and other revenue rose 20% to $4.18 million.
- Net loss per share of $0.24 was narrower than the consensus estimate of roughly $0.27, even as the absolute net loss widened to $7.46 million.
- Revenue of $12.08 million came in modestly below the approximately $12.30 million analyst consensus, a slight shortfall driven by segment mix.
- Cash and cash equivalents stood at about $46.2 million at quarter-end, supporting the company's ongoing integration and growth investments.
Why These Results Matter for Investors
ClearPoint Neuro is a commercial-stage medical device company focused on precise navigation for brain and spine procedures, along with preclinical services for drug and device delivery. The quarterly numbers are worth watching because the firm is scaling its top line while investing heavily in an expanded neurosurgery portfolio, including the IRRAflow catheter from the IRRAS transaction. This report provides an update on whether biologics partnerships, capital equipment placements, and the newer neurocritical care segment can maintain momentum even as the company stays unprofitable. After missing consensus estimates in recent quarters, the latest results also offer insight into whether execution is improving relative to Wall Street forecasts.
Breaking Down the Reported Numbers
For the three months ended September 30, 2026, CLPT reported total revenue of $12.08 million, up 36% from $8.86 million in the same period of 2025. Product revenue increased to $7.89 million from $5.36 million, and service and other revenue rose to $4.18 million from $3.50 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Gross profit rose to $7.06 million from $5.60 million, for a gross margin near 58%. Operating expenses increased, with sales and marketing climbing to $5.53 million from $3.84 million and R&D expenses moving to $4.02 million from $3.45 million. The operating loss widened to $6.33 million from $5.28 million, and the net loss reached $7.46 million, or $0.24 per share, versus a net loss of $5.89 million, or $0.21 per share, a year earlier.
Against expectations, the $0.24 per-share loss beat the consensus estimate of about $0.27, while revenue came in slightly below the roughly $12.30 million consensus. For the first nine months of 2026, revenue totaled $35.08 million, up from $26.56 million, with a net loss per share of $0.94.
Market Reaction and What Investors Are Watching
Heading into the report, sentiment around CLPT was cautious after eight straight quarters of missing consensus EPS estimates. Shares had traded well below their 52-week high amid concerns over widening losses and the costs of integrating the IRRAS business. The third-quarter results were mixed: the narrower-than-expected per-share loss offered some relief, but the modest revenue shortfall kept expectations measured.
Investors will likely focus on whether double-digit revenue growth can continue without further acceleration in operating losses. Rising sales and marketing spending remains an area of attention, as it pressures profitability even as revenue expands. Post-earnings trading will depend on management commentary about integration progress, cash burn, and the outlook for the biologics and drug delivery segment.
Forward Outlook and Key Factors to Monitor
Looking ahead, several elements stand out for CLPT. Execution on the IRRAS integration, especially adoption of the IRRAflow catheter in neurocritical care and expansion of the commercial team, will be central to broadening revenue beyond the core navigation business. The biologics and drug delivery segment is another key variable, as revenue here depends on the clinical trial activity and regulatory progress of pharmaceutical partners, which can introduce quarterly volatility.
Cost management will also draw scrutiny. With sales and marketing and R&D expenses rising faster than revenue, investors will watch whether gross margin improvements and operating leverage eventually narrow losses. The roughly $46 million cash balance provides runway, but continued investment means the path to profitability remains a multi-year story. Updates to full-year 2026 guidance and commentary on capital equipment placements will further shape expectations.
Using AI Tools in My Research Process
As part of my ongoing analysis of medical device names like CLPT, I frequently rely on Tickeron’s AI Screener to quickly compare fundamentals, technical patterns, and peer performance across the sector. The tool helps surface relevant data points and monitor shifts in market conditions without manual effort, which is especially useful when reviewing quarterly results and integration updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLPT sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for CLPT moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 82 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLPT entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Oscillator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where CLPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CLPT just turned positive on October 26, 2026. Looking at past instances where CLPT's MACD turned positive, the stock continued to rise in 41 of 54 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 216 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (27.430) is slightly higher than the industry average of (3.837). P/E Ratio (-8.212) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart.
Industry MedicalNursingServices
Advertisement